With the approval of maintenance therapy with olaparib and bevacizumab for high-grade ovarian cancer patients with a deficient homologous recombination pathway, the need for proper genomic testing emerged that not only enables the detection of BRCA1 and BRCA2 mutations, but also the evaluation of genomic instability. This evidence concerns the gene BRCA1 and ovarian carcinoma.